|
|
 |
|
|
|
Components
| AbbVie Inc. |
ABBV |
| ACADIA Pharmaceuticals Inc. |
ACAD |
| Alkermes Plc |
ALKS |
| Amgen Inc. |
AMGN |
| Arcellx, Inc. |
ACLX |
| Arvinas, Inc. |
ARVN |
| Beam Therapeutics Inc. |
BEAM |
| Biogen Inc. |
BIIB |
| BioMarin Pharmaceutical Inc. |
BMRN |
| Blueprint Medicines Corporation |
BPMC |
| Bristol-Myers Squibb Company |
BMY |
| Cardinal Health, Inc. |
CAH |
| Charles River Laboratories International, Inc. |
CRL |
| CRISPR Therapeutics AG |
CRSP |
| Elanco Animal Health Incorporated |
ELAN |
| Eli Lilly and Company |
LLY |
| Exact Sciences Corporation |
EXAS |
| Exelixis, Inc. |
EXEL |
| Gilead Sciences, Inc. |
GILD |
| Halozyme Therapeutics, Inc. |
HALO |
| IDEAYA Biosciences, Inc. |
IDYA |
| Illumina, Inc. |
ILMN |
| Incyte Corporation |
INCY |
| Intra-Cellular Therapies, Inc. |
ITCI |
| Ionis Pharmaceuticals, Inc. |
IONS |
| Jazz Pharmaceuticals Plc |
JAZZ |
| Johnson & Johnson |
JNJ |
| Krystal Biotech, Inc. |
KRYS |
| Kymera Therapeutics, Inc. |
KYMR |
| Medpace Holdings, Inc. |
MEDP |
| Merck & Co., Inc. |
MRK |
| Merus NV |
MRUS |
| MoonLake Immunotherapeutics (Class A) |
MLTX |
| Neurocrine Biosciences, Inc. |
NBIX |
| Nuvalent, Inc. (Class A) |
NUVL |
| Organon & Co. |
OGN |
| Perrigo Company Plc |
PRGO |
| Pfizer Inc. |
PFE |
| Prestige Consumer Healthcare Inc. |
PBH |
| Regeneron Pharmaceuticals, Inc. |
REGN |
| Rhythm Pharmaceuticals, Inc. |
RYTM |
| Roivant Sciences Ltd. |
ROIV |
| Sarepta Therapeutics, Inc. |
SRPT |
| TG Therapeutics, Inc. |
TGTX |
| Ultragenyx Pharmaceutical Inc. |
RARE |
| United Therapeutics Corporation |
UTHR |
| Vertex Pharmaceuticals Incorporated |
VRTX |
| Viatris Inc. |
VTRS |
| Viking Therapeutics, Inc. |
VKTX |
| Zoetis Inc. |
ZTS |
|
|
|
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|